Related Experiment Video

Updated: Aug 17, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Understanding novel therapeutic agents for multiple myeloma

Joseph D Tariman1

  • 1jtariman@nmff.org

Clinical Journal of Oncology Nursing
|November 8, 2003
PubMed

Insights

Multiple myeloma, a plasma cell cancer, is incurable. Novel agents like immunomodulatory drugs, proteasome inhibitors, and arsenic compounds offer new hope for patients with relapsed or refractory multiple myeloma.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Multiple myeloma is an incurable B cell malignancy.
  • Current treatments like chemotherapy and stem cell transplant improve survival but relapses are common.

Purpose of the Study:

  • To review novel therapeutic agents for relapsed or refractory multiple myeloma.
  • To focus on immunomodulatory drugs, proteasome inhibitors, and arsenic compounds.

Main Methods:

  • Literature review of recent clinical studies.
  • Analysis of therapeutic applications and efficacy of novel agents.

Main Results:

  • Novel agents demonstrate promising clinical utility.
  • Specific drug classes show potential in managing relapsed/refractory disease.

Conclusions:

  • New therapeutic strategies are crucial for improving outcomes in multiple myeloma.
  • Targeted agents offer new avenues for patients with resistant disease.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...